Use of non-occupational HIV post-exposure prophylaxis in Spain (2001-2005);Demanda y prescripción de la profilaxis postexposición no ocupacional al VIH en España (2001-2005)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 9, 2008, Pages 546-551

  Vives, Nuria ^a   Almeda, Jesús ^a,b   Contreras, Claudia A ^a   García, Felipe ^c   Campins, Magda ^d   Casabona, Jordi ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HIV; Non occupational exposure; Post exposure prophylaxis; Seroconversion; Side effects

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; ENVIRONMENTAL EXPOSURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; SEROCONVERSION; SPAIN; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

EID: 56549099235     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13128270     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention (United States). Public Health Service Guidelines for management of Health Care Workers exposure to HIV and recommendations for Post Exposure Prophylaxis. Morb Mortal Wkly Rep. 1998;47:1-28.
2. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. Update U.S. Public Health Service Guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. Morb Mortal Wkly Rep. 2005;54:1-17.
3. Saag MS. Candidate antiretroviral agents for use in post exposure prophylaxis. Am J Med. 1997;102:25-31.
4. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of post inoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIV infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265-73.
5. Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74:9771-5.
6. Black RJ. Animals studies of prophylaxis. Am J Med. 1997;102:39-44.
7. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485-90.
8. Connor EM, Sperling RS, Gelberg R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-80.
9. Centro de Estudios Epidemiológicos sobre el Sida de Cataluña (CEESCAT). Sistema integrado de vigilancia epidemiológica del VIH/ITS en Cataluña (SIVES). Informe anual. Barcelona: Generalitat de Cataluña, Departamento de Salud; 2005.
10. Centers for Disease Control and Prevention (United States). Public Health Service Opening of nonoccupational HIV postexposure prophylaxis registry. Morb Mortal Wkly Rep. 1999;48:496-7.
11. Correll P, Smith D, Grulich A. Post-exposure prophylaxis for non-occupational exposure to HIV: Experience in NSW one year after the introduction of the guidelines. NSW Public Health Bull. 2000;11:113-8.
12. CEESCAT. Informe final del Proyecto Europeo sobre Profilaxis Post-exposición no ocupacional al VIH (EURO-NONOPEP), Badalona, junio 2003. [Consultado el 4 mayo de 2007]. Disponible en: http://europa.eu.int/comm/ health/ph_projects/2000/com_diseases/fp_commdis_2000_frep_26_en.pdf
13. Bernasconi E, Jost J, Ledergerber B, Hirschel B, Francioli P, Sudre P. Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000. Swiss Med Wkly. 2001;131:433-7.
14. Lot F, Larsen C, Basselier B, Laporte A. Evaluation de la prise en charge thérapeutique des expositions au VIH, juillet 1999-décembre 2001. Bull Epidemiol Hebdomadaire. 2002;36:173-5.
15. Puro V, Govoni A, Mattioli F, De Carli G, Ippolito G. Italian PEP Registry Antiretroviral post-exposure prophylaxis in Italy. XIII International AIDS Conference; Durban, South Africa, 9-14 July 2000. [Abstract WePeC4420]
16. Almeda J, Casabona J, Simon B, Gerad M, Rey D, Puro V, et al. Proposed recommendations for the management of HIV post-exposure prophylaxis alter sexual, injecting drug or other exposures in Europe. Euro Surveill. 2004;9:35-40.
17. Grupo de consenso Español sobre profilaxis postexposición no ocupacional al VIH. Recomendaciones para la profilaxis postexposición no ocupacional al VIH. Med Clin (Barc). 2002;20:391-400.
18. Villes V, Enel P, Bentz L, Lafeuillade A, Diane MB, Rey D. Prophylaxie antirétrovirale après une exposition non professionnelle au VIH en Provence-Alpes-Côte d'Azur, 2001 et 2002. Bull Epidemiol Hebdomadaire. 2006;4:35-6.
19. Sonder GJ, Regez RM, Brinkman K, Prins JM, Mulder JW, Spaargaren J, et al. Prophylaxis and follow-up after possible exposure to HIV, hepatitis B virus, and hepatitis C virus outside hospital: evaluation of policy 2000-3. BMJ. 2005;330:825-9.
20. Kahn JO, Martin JM, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP study. J Infect Dis. 2001;183:707-14.
21. Sonder GJ, Van den Hoek A, Regez RM, Brinkman K, Prins JM, Mulder JW, et al. Trends in HIV Postexposure Prophylaxis Prescription and Compliance After Sexual Exposure in Amsterdam, 2000-2004. Sex Transm Dis. 2007;34:288-93.
22. Peña JM, Arribas JR. Profilaxis post-exposición no ocupacional al virus de la inmunodeficiencia humana: ¿espada de dos filos? Editorial. Enf Infecc Microbiol Clin. 2000;18:105-7.
23. Laporte A, Jourdan N, Bouvet E, Lamontagne F, Pillonel J, Desenclos JC. Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS. 2002;16:397-405.
24. Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, et al. Prescribing practices in a population-based HIV postexposure prophylaxis program. AIDS. 2002;16:1067-70.
25. Merchant RC, Keshavarz R. Emergency prophylaxis following leedle-stick injuries and sexual exposures: results from a survey comparing New Cork Emergency Department practicioners with their national colleagues. Mt Sinai J Med. 2003;70:338-43.
26. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Morb Mortal Wkly Rep. 2005;54:1-20.
27. Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39:395-401.
28. Puro V, De Carli G, Orchi N, Palvarini L, Chiodera A, Fantoni M, et al. Short term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents. 2001;15:238-42.
29. Rabaud C, Burty C, Grandidier M, Christian B, Penalba C, Beguinot I, et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis. 2005;40:303-5.
30. Puro V, De Carli G, Ippolito G; Italian Registry of Antiretroviral Post-Exposure Prophylaxis. Postexposure HIV prophylaxis regimen. Clin Infect Dis. 2004;39:395-401.
31. García F, Plana M, Mestre G, Cruceta A, Martínez E, Miro JM, et al. Metabolic and immunological effects of antiretroviral agents in healthy individuals receiving post-exposure prophylaxis. Antivir Ther. 2002;7:195-7.
32. Correll P, Smith D, Grulich A. Post-exposure prophylaxis for non-occupational exposure to HIV: experience in NSW one year after the introduction of the guidelines. NSW Public Health Bull. 2000;11:113-8.
33. Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, et al. Seroconversion Following Nonoccupational Postexposure Prophylaxis against HIV. Clin Infect Dis. 2005;41:1507-13.